Details of the Drug Combination

General Information of Drug Combination (ID: DCP0TND)

Drug Combination Name
ASP1941 Miglitol
Indication
Disease Entry Status REF
Type 2 Diabetes Mellitus Phase 1 [1]
Component Drugs ASP1941   DMGQ1TV Miglitol   DMXBQAM
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ASP1941
Disease Entry ICD 11 Status REF
Liver disease DB90-BD99 Phase 3 [2]
ASP1941 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of Miglitol
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [3]
Miglitol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Intestinal maltase-glucoamylase (MGAM) TTXWASR MGA_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Miglitol Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [6]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [6]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Secretion [6]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Decreases Expression [6]
Protein S100-A6 (S100A6) OTHHPZQ8 S10A6_HUMAN Decreases Expression [6]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Decreases Expression [6]
Protein S100-A11 (S100A11) OTI57KDN S10AB_HUMAN Decreases Expression [6]
Protein S100-A10 (S100A10) OTI71243 S10AA_HUMAN Decreases Expression [6]
Protein S100-A12 (S100A12) OTF9IIXW S10AC_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 ClinicalTrials.gov (NCT01242202) A Study to Assess the Safety and Efficacy of ASP1941 in Combination With -glucosidase Inhibitor in Type 2 Diabetic Patients
2 ClinicalTrials.gov (NCT01054092) A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4842).
4 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
5 Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
6 The -glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 2010 Dec;59(12):1816-22. doi: 10.1016/j.metabol.2010.06.006. Epub 2010 Jul 29.